PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DB23FR2TX4561987109!farxiga 10 MG TABLET 30s — Amerisourcebergen Drug Corp

Amerisourcebergen Drug Corp holds $19.3B across 1,357,999 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DB22D2218. PoP ended Aug 30, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support
Awarding office
Amerisourcebergen Drug Corp
Recipient
Aug 30, 2023
PoP end
$120K
Obligated
$120K
Potential
424210
NAICS
6505
PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Amerisourcebergen Drug Corp — $90

Contract facts

Federal
Contract numberSPE2DB23FR2TX
Also listed asSPE2DB22D2218-SPE2DB23FR2TX
AgencyDla Troop Support
Awarding officeDla Troop Support
Awarding agencyDepartment of Defense (DOD)
Funding agencyDepartment of Defense (DOD)
IncumbentAmerisourcebergen Drug Corp
CAGE1XUY5
UEIKABZK8W6PQT3
NAICS424210

No full NAICS 424210 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDVSPE2DB22D2218
Place of performanceCONSHOHOCKEN PA
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startAug 29, 2023
PoP end (current)Aug 30, 2023
Obligated$120K
Current value$120K
Potential value$120K

4561987109!FARXIGA 10 MG TABLET 30S is a federal award for Dla Troop Support held by Amerisourcebergen Drug Corp. Estimated value $120K ($120K obligated). Current period of performance ends Aug 30, 2023. Place of performance: CONSHOHOCKEN PA.

Recompete timing

Public
Past PoP end (1087 days ago)

Current PoP ended Aug 30, 2023 (1087 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Amerisourcebergen Drug Corp$19.3B obligated across 1,357,999 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($19.3B) · all agencies
Department of Defense (DOD)$19.3B · 100%Department of Health and Human Services (HHS)$7.6M · 0%Department of Veterans Affairs (VA)$5.9M · 0%Department of Justice (DOJ)$68K · 0%
Open full company profile

Related awards

Same parent · incumbent
36C77026P0121
DROSPIRENONE
$321K
Sep 27, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract SPE2DB23FR2TX?

SPE2DB23FR2TX (4561987109!farxiga 10 MG TABLET 30s) is a Dla Troop Support award with a potential value of $120K, currently held by Amerisourcebergen Drug Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DB23FR2TX?

Dla Troop Support awarded SPE2DB23FR2TX to Amerisourcebergen Drug Corp (potential $120K).

Who is the incumbent on SPE2DB23FR2TX?

Amerisourcebergen Drug Corp is the incumbent with $19.3B across 1357999 related awards in SCOUT’s public footprint. The current period of performance ends Aug 30, 2023.

When does Amerisourcebergen Drug Corp’s SPE2DB23FR2TX come up for recompete?

SCOUT tracks a period-of-performance end of Aug 30, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/SPE2DB23FR2TX